RT Journal Article
SR Electronic
T1 Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <em>BRAF</em> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e004226
DO 10.1136/jitc-2021-004226
VO 10
IS 6
A1 Tawbi, Hussein A
A1 Robert, Caroline
A1 Brase, Jan C
A1 Gusenleitner, Daniel
A1 Gasal, Eduard
A1 Garrett, James
A1 Savchenko, Alexander
A1 Görgün, Güllü
A1 Flaherty, Keith T
A1 Ribas, Antoni
A1 Dummer, Reinhard
A1 Schadendorf, Dirk
A1 Long, Georgina V
A1 Nathan, Paul D
A1 Ascierto, Paolo A
YR 2022
UL http://jitc.bmj.com/content/10/6/e004226.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.